FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1980762985> ?p ?o ?g. }

• W1980762985 endingPage "1445" @default.
• W1980762985 startingPage "1437" @default.
• W1980762985 abstract "Purpose We compared biweekly irinotecan plus cisplatin (BIRIP) with irinotecan alone as the second-line chemotherapy (SLC) for advanced gastric cancer (AGC). Methods Patients with metastatic or recurrent gastric cancer refractory to S-1-based first-line chemotherapy were randomly assigned to receive BIRIP (irinotecan 60 mg/m2 plus cisplatin 30 mg/m2, every 2 weeks) or irinotecan alone (irinotecan 150 mg/m2, every 2 weeks). The primary end-point was to show the superiority of BIRIP to irinotecan in terms of progression free survival (PFS). Results 130 patients were enrolled. PFS was significantly longer in the BIRIP group (3.8 months [95% confidence interval (CI) 3.0–4.7]) than in the irinotecan group (2.8 months [ 2 Van Cutsem E. Moiseyenko V.M. Tjulandin S. et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006; 24: 4991-4997 Crossref PubMed Scopus (1742) Google Scholar , 3 Koizumi W. Narahara H. Hara T. et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008; 9: 215-221 Abstract Full Text Full Text PDF PubMed Scopus (1797) Google Scholar ]; hazard ratio 0.68, 95% CI 0.47–0.98; P= 0.0398). Median overall survival was 10.7 months in the BIRIP group and 10.1 months in the irinotecan group (HR 1.00, 95% CI 0.69–1.44, P= 0.9823). The objective response rate was 22% in the BIRIP group and 16% in the irinotecan group (P= 0.4975). However, the disease control rate was significantly better in the BIRIP group (75%) than in the irinotecan group (54%, P= 0.0162). The incidences of grade 3 or worse adverse events did not differ between the two groups. Any grade elevation of serum creatinine was more common in the BIRIP group (25% versus 8%, P= 0.009), but any grade diarrhoea (17% versus 42%, P= 0.002) was more common in the irinotecan group. Conclusion BIRIP significantly prolonged PFS as compared with irinotecan alone and was tolerated as SLC, but did not demonstrate the survival benefit in this trial." @default.
• W1980762985 created "2016-06-24" @default.
• W1980762985 creator A5000521371 @default.
• W1980762985 creator A5008454101 @default.
• W1980762985 creator A5011441657 @default.
• W1980762985 creator A5011551950 @default.
• W1980762985 creator A5011974412 @default.
• W1980762985 creator A5016038702 @default.
• W1980762985 creator A5020684025 @default.
• W1980762985 creator A5038876397 @default.
• W1980762985 creator A5040745867 @default.
• W1980762985 creator A5041641476 @default.
• W1980762985 creator A5042750898 @default.
• W1980762985 creator A5054389401 @default.
• W1980762985 creator A5068425977 @default.
• W1980762985 creator A5071422219 @default.
• W1980762985 creator A5076136934 @default.
• W1980762985 creator A5078734873 @default.
• W1980762985 creator A5090659723 @default.
• W1980762985 date "2014-05-01" @default.
• W1980762985 modified "2023-09-27" @default.
• W1980762985 title "Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial)" @default.
• W1980762985 cites W1525737532 @default.
• W1980762985 cites W1976651872 @default.
• W1980762985 cites W2003772907 @default.
• W1980762985 cites W2008575122 @default.
• W1980762985 cites W2057331147 @default.
• W1980762985 cites W2072279142 @default.
• W1980762985 cites W2097820456 @default.
• W1980762985 cites W2104631255 @default.
• W1980762985 cites W2104759721 @default.
• W1980762985 cites W2114734455 @default.
• W1980762985 cites W2122866527 @default.
• W1980762985 cites W2137991416 @default.
• W1980762985 cites W2147302668 @default.
• W1980762985 cites W2164411042 @default.
• W1980762985 cites W2171075804 @default.
• W1980762985 doi "https://doi.org/10.1016/j.ejca.2014.01.020" @default.
• W1980762985 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24560487" @default.
• W1980762985 hasPublicationYear "2014" @default.
• W1980762985 type Work @default.
• W1980762985 sameAs 1980762985 @default.
• W1980762985 citedByCount "65" @default.
• W1980762985 countsByYear W19807629852014 @default.
• W1980762985 countsByYear W19807629852015 @default.
• W1980762985 countsByYear W19807629852016 @default.
• W1980762985 countsByYear W19807629852017 @default.
• W1980762985 countsByYear W19807629852018 @default.
• W1980762985 countsByYear W19807629852019 @default.
• W1980762985 countsByYear W19807629852020 @default.
• W1980762985 countsByYear W19807629852021 @default.
• W1980762985 countsByYear W19807629852022 @default.
• W1980762985 countsByYear W19807629852023 @default.
• W1980762985 crossrefType "journal-article" @default.
• W1980762985 hasAuthorship W1980762985A5000521371 @default.
• W1980762985 hasAuthorship W1980762985A5008454101 @default.
• W1980762985 hasAuthorship W1980762985A5011441657 @default.
• W1980762985 hasAuthorship W1980762985A5011551950 @default.
• W1980762985 hasAuthorship W1980762985A5011974412 @default.
• W1980762985 hasAuthorship W1980762985A5016038702 @default.
• W1980762985 hasAuthorship W1980762985A5020684025 @default.
• W1980762985 hasAuthorship W1980762985A5038876397 @default.
• W1980762985 hasAuthorship W1980762985A5040745867 @default.
• W1980762985 hasAuthorship W1980762985A5041641476 @default.
• W1980762985 hasAuthorship W1980762985A5042750898 @default.
• W1980762985 hasAuthorship W1980762985A5054389401 @default.
• W1980762985 hasAuthorship W1980762985A5068425977 @default.
• W1980762985 hasAuthorship W1980762985A5071422219 @default.
• W1980762985 hasAuthorship W1980762985A5076136934 @default.
• W1980762985 hasAuthorship W1980762985A5078734873 @default.
• W1980762985 hasAuthorship W1980762985A5090659723 @default.
• W1980762985 hasConcept C121608353 @default.
• W1980762985 hasConcept C126322002 @default.
• W1980762985 hasConcept C143998085 @default.
• W1980762985 hasConcept C207103383 @default.
• W1980762985 hasConcept C2776694085 @default.
• W1980762985 hasConcept C2778239845 @default.
• W1980762985 hasConcept C2780259306 @default.
• W1980762985 hasConcept C2780739268 @default.
• W1980762985 hasConcept C2781190966 @default.
• W1980762985 hasConcept C44249647 @default.
• W1980762985 hasConcept C526805850 @default.
• W1980762985 hasConcept C71924100 @default.
• W1980762985 hasConcept C90924648 @default.
• W1980762985 hasConceptScore W1980762985C121608353 @default.
• W1980762985 hasConceptScore W1980762985C126322002 @default.
• W1980762985 hasConceptScore W1980762985C143998085 @default.
• W1980762985 hasConceptScore W1980762985C207103383 @default.
• W1980762985 hasConceptScore W1980762985C2776694085 @default.
• W1980762985 hasConceptScore W1980762985C2778239845 @default.
• W1980762985 hasConceptScore W1980762985C2780259306 @default.
• W1980762985 hasConceptScore W1980762985C2780739268 @default.
• W1980762985 hasConceptScore W1980762985C2781190966 @default.
• W1980762985 hasConceptScore W1980762985C44249647 @default.
• W1980762985 hasConceptScore W1980762985C526805850 @default.
• W1980762985 hasConceptScore W1980762985C71924100 @default.
• W1980762985 hasConceptScore W1980762985C90924648 @default.
• W1980762985 hasIssue "8" @default.

• next